Innovus Pharmaceuticals Inactive 10-Q2015 Q3 Quarterly report

Filed: 16 Nov 15, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Bad

New words: AndroVit, Bangladesh, Bhutan, bifurcated, Black, bundled, buy, cancelation, canceled, Carlo, categorized, CFO, coupon, coverage, cranberry, cure, Europe, forfeited, formula, fulfilled, higher, hour, India, Indian, Khandelwal, Lanka, local, maintain, Marcocarpon, methodology, modification, Monte, multiplied, Nepal, OID, pronouncement, prostate, quantitative, raw, release, released, simulation, Somalia, spread, Sri, Subcontinent, summary, Syria, thereon, unamortized, Vaccinium, XR

Removed: achieve, Algeria, alleviated, allocate, Arabia, assessment, beneficially, California, commercially, conventional, converting, core, depict, discharging, DJS, doubt, dysfunction, Egypt, evaluate, extinguishment, female, footnote, formal, implicit, incorporating, Iraq, Jordan, Kingdom, Libya, measuring, Middle, mitigating, Morocco, multiple, Nasdaq, North, offering, offsetting, prohibited, promised, receipt, recognize, redeem, responsibility, Saudi, substantial, supplied, Territory, tested, treatment, Tunisia, wholly

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Innovus Pharmaceuticals similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Innovus Pharmaceuticals, Inc. (the “Corporation”) for the quarter ended March 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Bassam Damaj, principal executive officer of the Corporation, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Corporation as of September 30, 2015.

Dated: November 16, 2015		/s/ Bassam Damaj
		Bassam Damaj, President and Chief Executive Officer (Chief Executive and Financial Officer)